167 related articles for article (PubMed ID: 32307496)
1. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations.
Li L; Li X; Tang Y; Lao Z; Lei J; Wei G
Phys Chem Chem Phys; 2020 May; 22(17):9225-9232. PubMed ID: 32307496
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation.
Lei J; Cai M; Shen Y; Lin D; Deng X
Phys Chem Chem Phys; 2021 Oct; 23(40):23032-23041. PubMed ID: 34612239
[TBL] [Abstract][Full Text] [Related]
3. Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer.
Pedrote MM; de Oliveira GAP; Felix AL; Mota MF; Marques MA; Soares IN; Iqbal A; Norberto DR; Gomes AMO; Gratton E; Cino EA; Silva JL
J Biol Chem; 2018 Jul; 293(29):11374-11387. PubMed ID: 29853637
[TBL] [Abstract][Full Text] [Related]
4. Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53.
Song B; Wang J; Ren Y; Su Y; Geng X; Yang F; Wang H; Zhang J
Biomed Pharmacother; 2023 Jul; 163():114773. PubMed ID: 37156116
[TBL] [Abstract][Full Text] [Related]
5. Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.
Kamaraj B; Bogaerts A
PLoS One; 2015; 10(8):e0134638. PubMed ID: 26244575
[TBL] [Abstract][Full Text] [Related]
6. Insights into Allosteric Mechanisms of the Lung-Enriched p53 Mutants V157F and R158L.
Lei J; Li X; Cai M; Guo T; Lin D; Deng X; Li Y
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077492
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol.
Liu Q; Li L; Yu Y; Wei G
J Phys Chem B; 2023 Sep; 127(36):7708-7720. PubMed ID: 37665658
[TBL] [Abstract][Full Text] [Related]
8. Hot-spot mutants of p53 core domain evince characteristic local structural changes.
Wong KB; DeDecker BS; Freund SM; Proctor MR; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8438-42. PubMed ID: 10411893
[TBL] [Abstract][Full Text] [Related]
9. Mutations in DNA binding domain of p53 impede RSL1D1-p53 interaction to escape from degradation in human colorectal cancer cells.
Ding L; Zhao C; Xu Y; Zhang Z; Nie Y; Liao K; Chen Y; Tu B; Zhang X
Exp Cell Res; 2022 Aug; 417(1):113211. PubMed ID: 35597299
[TBL] [Abstract][Full Text] [Related]
10. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
12. Dynamics and Molecular Mechanisms of p53 Transcriptional Activation.
Offutt TL; Ieong PU; Demir Ö; Amaro RE
Biochemistry; 2018 Nov; 57(46):6528-6537. PubMed ID: 30388364
[TBL] [Abstract][Full Text] [Related]
13. Biophysical characterization of p53 core domain aggregates.
Lima I; Navalkar A; Maji SK; Silva JL; de Oliveira GAP; Cino EA
Biochem J; 2020 Jan; 477(1):111-120. PubMed ID: 31841126
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic Differences in Backbone Dynamics between Wild Type and DNA-Contact Mutants of the p53 DNA Binding Domain Revealed by Nuclear Magnetic Resonance Spectroscopy.
Rasquinha JA; Bej A; Dutta S; Mukherjee S
Biochemistry; 2017 Sep; 56(37):4962-4971. PubMed ID: 28836764
[TBL] [Abstract][Full Text] [Related]
15. Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket.
Pradhan MR; Siau JW; Kannan S; Nguyen MN; Ouaray Z; Kwoh CK; Lane DP; Ghadessy F; Verma CS
Nucleic Acids Res; 2019 Feb; 47(4):1637-1652. PubMed ID: 30649466
[TBL] [Abstract][Full Text] [Related]
16. Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy.
Olotu FA; Soliman MES
J Cell Biochem; 2019 Jan; 120(1):951-966. PubMed ID: 30160791
[TBL] [Abstract][Full Text] [Related]
17. Tumorigenic p53 mutants undergo common structural disruptions including conversion to α-sheet structure.
Bromley D; Daggett V
Protein Sci; 2020 Sep; 29(9):1983-1999. PubMed ID: 32715544
[TBL] [Abstract][Full Text] [Related]
18. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
[TBL] [Abstract][Full Text] [Related]
19. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.
Garufi A; Trisciuoglio D; Porru M; Leonetti C; Stoppacciaro A; D'Orazi V; Avantaggiati M; Crispini A; Pucci D; D'Orazi G
J Exp Clin Cancer Res; 2013 Oct; 32(1):72. PubMed ID: 24220325
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.
Sankala H; Vaughan C; Wang J; Deb S; Graves PR
Arch Biochem Biophys; 2011 Aug; 512(1):52-60. PubMed ID: 21621504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]